Form 4: Edgewise Therapeutics Director Receives Stock Option Grant

Director Jonathan C. Fox was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Jonathan C. Fox received a grant of 16,377 stock options on June 5, 2026.
• The options have an exercise price of $35.59 per share.
• The options are scheduled to vest in full on the earlier of June 5, 2027, or the business day prior to the 2027 annual meeting of stockholders.
• The options expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.59 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 5, 2027, or the day before the 2027 annual meeting.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Director Compensation, Stock Options, Insider Transaction, Form 4